R-Idaram is named as a drug or biological intervention in 2 clinical trials in our China trial register, 2 of which are recruiting. The lead sponsor is Navy General Hospital, Beijing. Registered phase: Phase 2/3. Conditions studied include Primary Central Nervous System Lymphoma.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT02657785 | Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy (ClinicalTrials.gov ↗) Primary Central Nervous System Lymphoma |
Phase 2/3 | Recruiting |
| NCT02836158 | Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL (ClinicalTrials.gov ↗) Primary Central Nervous System Lymphoma |
Phase 2/3 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Primary Central Nervous System Lymphoma | 2 |
| Lead sponsor | Trials |
|---|---|
| Navy General Hospital, Beijing | 2 |
| Register | R-Idaram trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how R-Idaram works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists R-Idaram (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.